# ***Vascular Medicine* Twitter Journal Club Agenda**

**Topic: Management of intermediate/high-risk pulmonary embolism**

**When:** Tuesday, September 15, 2020 @ 8-9 pm EST

**Where:** The discussion takes place on Twitter. Click on[@VMJ\_SVM](https://twitter.com/VMJ_SVM) or search for [#VascMedJC](https://twitter.com/search?f=tweets&vertical=default&q=%23VascMedJC&src=typd) on Twitter.

**Facilitator:** Alec Schmaier ([@ASchmaier](https://twitter.com/ASchmaier)), Social Media Editor for Vascular Medicine

**Article to be discussed:**

**Outcomes of catheter-directed versus systemic thrombolysis for the treatment of pulmonary embolism: A real-world analysis of national administrative claims**

Bram J Geller, Srinath Adusumalli, Steven C Pugliese, Sameed Ahmed M Khatana, Ashwin Nathan, Ido Weinberg, Michael R Jaff, Taisei Kobayashi, Jeremy A Mazurek, Sameer Khandhar, Lin Yang, Peter W Groeneveld, Jay S Giri

*Vasc Med* 2020; 25:335-340. DOI: [https://doi.org/10.1177/1358863X20903371](https://doi.org/10.1177%2F1358863X20903371)

**Planned Discussion Questions:**

1. #VascMedJC Q1: #PE is the third-leading cause of cardiac death and often a cause of sudden cardiac death, why has it been so challenging to develop prospective randomized clinical trials for catheter directed thrombolysis (CDT) for PE?
2. #VascMedJC Q2: How do the findings of this paper reflect your current practice regarding treatment of #PE with catheter-directed thrombolisys?
3. #VascMedJC Q3: Catheter-directed technology continues to advance for #PE. Are there invasive options commonly used today that weren’t present in the cohort studied from 2004-2014 by Geller et al?
4. #VascMedJC Q4: Because of lower total doses of tPA, CDT is often considered a ‘safer’ option compared to systemic thrombolysis. What are some reasons why bleeding may be more common in the CDT cohort?
5. #VascMedJC Q5: What might be a better population for further study on CDT—patients with intermediate or high-risk #PE on presentation or intermediate-risk patients who fail to improve despite adequate anticoagulation?

**CME Opportunity:**

One (1) continuing medical education (CME) credit and one (1) maintenance of certification (MOC) point are available for participating in the *Vascular Medicine* Journal Club. This opportunity is made possible through a joint partnership with University of Virginia School of Medicine (UVASOM). There are no fees to participate in the activity or claim credit; however, there may be a fee to download the article from the *Vascular Medicine* website if you do not have an active subscription or journal access.

To be eligible for credit, participants must contribute to the 1-hour Journal Club discussion using “**#VascMedJC”.** Tweets without the hashtag will not be counted. After the session, participants must complete the post-activity evaluation and MOC questions. Visit the SVM website for complete details and instructions: <https://www.vascularmed.org/i4a/pages/index.cfm?pageid=3510>.

**Reminders:**

* Please use the hashtag #VascMedJC on all tweets
* When responding to a tweet, choose retweet with comment/quote tweet (don’t just directly reply)
* After the session is over, remember to claim your CME and MOC credits.